Cryoport and the Cell and Gene Therapy Catapult have entered into a new strategic partnership to support the advancement of cell and gene therapies.
As part of the deal, Cryoport will establish a Good Manufacturing Practice (GMP)-compliant global supply chain logistics centre in the UK at the CGT Catapult’s large-scale cell and gene therapy Stevenage Manufacturing Innovation Centre.
“The cell and gene therapy industry has become an area of rapid growth in the UK with increasing governmental support, making now the prime opportunity to partner with CGT Catapult to offer advanced therapy manufacturers streamlined solutions for their cold chain logistics needs,” said Jerrell Shelton, CEO of Cryoport.
Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, added: “The services Cryoport offers will support the continued growth of the industry, by strengthening even further the established global supply chains from the UK, and we look forward to the future success of Cryoport in the UK.”
